Disufenton
Alternative Names: Cerovive; CPI 22; Disufenton sodium; NXY 059; NXY 059GLatest Information Update: 16 Jan 2022
At a glance
- Originator Renovis
- Class Anti-ischaemics; Antineoplastics; Benzenesulfonates; Neuroprotectants; Nitrogen oxides; Small molecules
- Mechanism of Action Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 01 Nov 2006 Results from the phase III clinical trial SAINT II in patients with acute ischaemic stroke have been added to the adverse events and Neurological disorders therapeutic trials sections ,
- 26 Oct 2006 Discontinued - Phase-III for Stroke in Asia, Australia, Canada, Europe, New Zealand, South Africa, South America, Sweden, United Kingdom, USA and Japan (IV-infusion)
- 02 Aug 2006 Renovis has completed enrolment in the SAINT II trial for acute ischaemic stroke